MON-606 Efficacy of Continuous Glucose Monitoring in Diabetes Management of Underserved Populations

Abstract Disclosure: J. Vidovic: None. A. Deng: None. T. Mitsuuchi: None. M. Weber: None. J. Lin: None. K. Cheng: None. A. Thirumalai: None. Introduction and Objective: Low-income individuals with type 2 diabetes (T2D) who rely on Medicaid or institutional financial assistance often have disparate coverage of diabetes technology compared to other patients. Access to continuous glucose monitor (CGM) technology has significant benefits in insulin treated diabetes patients, a cohort underprivileged communities are enriched with. The objective of this study was to evaluate the impact of CGM use in insulin-treated T2D patients who do not qualify for such coverage through the current restrictions of their Medicaid plans or financial assistance. Methods: Adults with T2DM who were treated with 1 or more injections of insulin daily and A1c > 7%, who did not meet insurance criteria for CGM coverage through institutional financial assistance or Washington State Medicaid were supplied with a Freestyle libre (2 or 3) CGM system for 6 months, through the “Healthier Here” grant. Data was collected at baseline, 2 weeks, 3 months and 6 months and compared to a control group that used a glucose meter. We previously reported changes in A1C and CGM metrics at 3 months for a subset of the population and currently present updated results of the larger cohort through 6 months. Results: Forty adults with T2D were enrolled: 55% covered by financial assistance and 45% by Medicaid. Mean age of patients was 56 years, T2D duration 7.6 years, 45% were female, 67.5% were Hispanic, 15% Black, 12.5% White, 7.5% Asian, 2.5% Native Hawaiian or Pacific Islander and 2.5% Other. Baseline mean A1c was 9.55% ±1.5 vs A1c 8.86% ±1.78 (n = 36) in the control group, mean number of diabetes medications was 3.03 and mean glucose checks were 1.1 per day. In the intervention arm, A1c decreased from baseline by -1.52% ± 1.76 (n=30) at 3 months and -1.35% ± 2.04 (n=27) at 6 months; in the control group A1c decreased by -0.96% ± 2.26 (n=26) at 3 months and -0.83% ± 2.49 (n=36) at 6 months. Sensor usage remained >70% throughout the study period. Mean Time In Range (70-180 mg/dL; TIR) increased from 50.14 ±24.50 % at 2 weeks to 52.90 ± 23.59 % and 56.52±23.30 % at 3 months and 6 months respectively. Mean CGM glucose decreased from 194.7 ± 47.09 mg/dL at 2 weeks to 191.50 ±43.09 and 184.55 ±36.11 mg/dL at 3 and 6 months, respectively. Mean Time Below Range (<70 and <54 mg/dL; TBR) did not change significantly. At 3 months mean number of diabetes medications was 3.18 ± 0.92 and at 6 months 2.78 ± 0.75. Conclusion: CGM use showed notable improvements in glycemia in patients with financial assistance or medicaid insurance plans who did not meet current restrictive coverage policies. Presentation: Monday, July 14, 2025